Workman P - Search Results

1

From darkness to light with biomarkers in early clinical trials of cancer drugs.

Carden CP, Banerji U, Kaye SB, Workman P, de Bono JS. Carden CP, et al. Among authors: workman p. Clin Pharmacol Ther. 2009 Feb;85(2):131-3. doi: 10.1038/clpt.2008.223. Clin Pharmacol Ther. 2009. PMID: 19151637 Review.

2

Laboratory and phase I studies of new cancer drugs.

Workman P, Kaye SB, Schwartsmann G. Workman P, et al. Curr Opin Oncol. 1992 Dec;4(6):1065-72. doi: 10.1097/00001622-199212000-00011. Curr Opin Oncol. 1992. PMID: 1360819 Review.

3

Pharmacokinetics and early clinical studies of selected new drugs.

Kaye SB, Workman P, Graham MA, Cassidy J, Jodrell D. Kaye SB, et al. Among authors: workman p. Cancer Surv. 1993;17:371-96. Cancer Surv. 1993. PMID: 8137348 Review.

4

Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.

Graham MA, Senan S, Robin H Jr, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, Workman P. Graham MA, et al. Among authors: workman p. Cancer Chemother Pharmacol. 1997;40(1):1-10. doi: 10.1007/s002800050617. Cancer Chemother Pharmacol. 1997. PMID: 9137522 Clinical Trial.

5

Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.

Senan S, Rampling R, Graham MA, Wilson P, Robin H Jr, Eckardt N, Lawson N, McDonald A, von Roemeling R, Workman P, Kaye SB. Senan S, et al. Among authors: workman p. Clin Cancer Res. 1997 Jan;3(1):31-8. Clin Cancer Res. 1997. PMID: 9815534 Clinical Trial.

6

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, Judson I, Workman P. Clarke PA, et al. Among authors: workman p. Oncogene. 2000 Aug 24;19(36):4125-33. doi: 10.1038/sj.onc.1203753. Oncogene. 2000. PMID: 10962573

7

Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo.

Sharp SY, Kelland LR, Valenti MR, Brunton LA, Hobbs S, Workman P. Sharp SY, et al. Among authors: workman p. Mol Pharmacol. 2000 Nov;58(5):1146-55. doi: 10.1124/mol.58.5.1146. Mol Pharmacol. 2000. PMID: 11040064

8

Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol.

Smith V, Raynaud F, Workman P, Kelland LR. Smith V, et al. Among authors: workman p. Mol Pharmacol. 2001 Nov;60(5):885-93. doi: 10.1124/mol.60.5.885. Mol Pharmacol. 2001. PMID: 11641415

9

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.

Clarke PA, te Poele R, Wooster R, Workman P. Clarke PA, et al. Among authors: workman p. Biochem Pharmacol. 2001 Nov 15;62(10):1311-36. doi: 10.1016/s0006-2952(01)00785-7. Biochem Pharmacol. 2001. PMID: 11709192 Review.

10

Translating basic cancer research into new cancer therapeutics.

Workman P, Kaye SB. Workman P, et al. Trends Mol Med. 2002;8(4 Suppl):S1-9. doi: 10.1016/s1471-4914(02)02319-5. Trends Mol Med. 2002. PMID: 11927279 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

606 results

Search Page

Filters